| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Elevated Levels of Serum-Free Light Chains Linked to Increased Risk of Lymphoma in Patients With HIV: Presented at AIDS 2010 By Jenny Powers VIENNA -- July 23, 2010 -- The presence of elevated levels of serum-free light chains (sFLC) are a strong and sensitive marker for the risk of patients with HIV developing non-Hodgkin's Lymphoma and Hodgkin's Disease, researchers said here at the 18th International AIDS Conference. Furthermore, longer combined anti-retroviral treatment (ART) duration was associated with a longer period of viraemia suppression and decreased risk of developing non-Hodgkin's Lymphoma or Hodgkin's Disease. Maria Paola Trotta, MD, Istituto Nazionale Malattie Infettive Spallanzani, Rome, Italy presented results here on July 21. The study included patients with HIV who were also diagnosed with either non-Hodgkin's Lymphoma or Hodgkin's Disease, who were a subgroup of a case control study that enrolled 6,500 participants during a 10-year period from 1997 to 2007. Of these patients, a total of 138 samples from 46 patients with non-Hodgkin's Lymphoma (n = 30) and Hodgkin's Disease (n = 16) were matched by sex, age, and distance from diagnosis/selection with controls. All samples were assessed for quantitative levels of sFLC. Logistic regression was used to determine the relationship between sFLC levels and diagnosis. The sFLC levels were significantly higher in patients with lymphoma than in controls (P =.003), making sFLC a predictive marker for the risk of non-Hodgkin's Lymphoma and Hodgkin's Disease that was statistically independent of CD4 counts. Longer duration of suppressed viraemia (<400 copies/mL) was independently associated with decreased sFLC levels and a lower risk of lymphoma. It was observed that patients with >50% of normal threshold at most recent sample (0-3 years) showed an increased risk of lymphoma than patients with equal levels at earlier samples dates; it was concluded that a study that included sequential sampling could define this trend. [Presentation title: Role of Serum Free Light Chains (sFLC) in Predicting HIV-Associated Non Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD) and Its Correlation With Effective Combined Antiretroviral Treatment (cART). Abstract TUPDB102]
|